US2022017607A1PendingUtilityA1

Monoclonal antibodies against amyloid beta protein and uses thereof

76
Assignee: ABBVIE INCPriority: Nov 30, 2005Filed: Feb 22, 2021Published: Jan 20, 2022
Est. expiryNov 30, 2025(expired)· nominal 20-yr term from priority
Inventors:Heinz HillenStefan BarghornBoris LabkovskyUlrich EbertAndreas StriebingerPatrick Keller
G01N 2800/2821G01N 2500/20C07K 2317/565A61K 2039/505C07K 2317/14C07K 2317/24G01N 33/577C07K 2317/92C07K 2317/56A61P 25/28C07K 2317/21A61K 39/3955G01N 2333/4709A61P 37/04C07K 2317/20C07K 16/18G01N 33/6896G01N 33/53C07K 16/46G01N 33/6893
76
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The subject invention relates to monoclonal antibodies (e.g., 8F5 and 8C5) that may be used, for example, in the prevention, treatment, and diagnosis of Alzheimer's Disease or other neurodegenerative disorders.

Claims

exact text as granted — not AI-modified
1 .- 6 . (canceled) 
     
     
         7 . A hybridoma having American Type Culture Collection designation number PTA-7238. 
     
     
         8 .- 56 . (canceled)

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.